NCT04629703Phase 3Completed

Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

Study sponsor: Rigel Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2022-09-05Actual
Enrollment · participants280Actual
Source updated2023-08-18Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.